Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
ATP-Binding Cassette Transporters
/ genetics
Anaplastic Lymphoma Kinase
/ antagonists & inhibitors
Animals
Apoptosis
Biomarkers, Tumor
Carbazoles
/ pharmacology
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Proliferation
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Gene Rearrangement
Humans
Lung Neoplasms
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Nude
Piperidines
/ pharmacology
Protein Kinase Inhibitors
/ pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
09
07
2019
revised:
04
01
2020
accepted:
19
03
2020
pubmed:
29
3
2020
medline:
29
4
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Alectinib is used as a first-line treatment for anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Whereas other ALK inhibitors have been reported to be involved in resistance to ATP-binding cassette (ABC) transporters, no data are available regarding the association between resistance to alectinib and ABC-transporters. To investigate whether ABC-transporters contribute to alectinib resistance, ABC-transporter expression in alectinib-resistant cell lines derived from a patient with ALK-rearranged NSCLC and from H2228 lung cancer cells was evaluated and compared with that in each parent cell type. ATP-binding cassette subfamily C member 11 (ABCC11) expression was significantly increased in alectinib-resistant cell lines compared with that in alectinib-sensitive lines. ABCC11 inhibition increased sensitivity to alectinib
Identifiants
pubmed: 32217741
pii: 1535-7163.MCT-19-0649
doi: 10.1158/1535-7163.MCT-19-0649
doi:
Substances chimiques
ABCC11 protein, human
0
ATP-Binding Cassette Transporters
0
Biomarkers, Tumor
0
Carbazoles
0
Piperidines
0
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
alectinib
LIJ4CT1Z3Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1320-1327Informations de copyright
©2020 American Association for Cancer Research.